Latest news
The AMR Pipeline Is Too Thin for the Threat Ahead
The 2026 AMR Benchmark shows that industry efforts are still being outpaced by drug resistance, with antimicrobial innovation, access, stewardship and manufacturing all under pressure.
WHO Makes Obesity Treatment a Global Access Test
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
AI Mental Health Support Becomes a Governance Test
Alzheimer’s Drugs Force NICE Back Into the Value Debate
Europe Starts Treating Brain Health as System Resilience
